Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine-Reference-Cited by-同舟云学术

Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine

Published:2015-04-02 Issue:1 Volume:102 Page:53-58
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Nishikori Momoko,Kitano Toshiyuki,Kobayashi Masayuki,Hishizawa Masakatsu,Kitawaki Toshio,Kondo Tadakazu,Yamashita Kouhei,Kawabata Hiroshi,Kadowaki Norimitsu,Takei Yusuke,Haga Hironori,Takaori-Kondo Akifumi

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-015-1791-3.pdf

Reference22 articles.

1. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–10.

2. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine–rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944–52.

3. Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31:2103–9.

4. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29:3559–66.

5. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209–16.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Time to Onset of Bendamustine-associated Skin Damage Using the Spontaneous Reporting System;Anticancer Research;2022-04-30

2. Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy;Journal of Clinical and Experimental Hematopathology;2022

3. Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma;Journal of Clinical and Experimental Hematopathology;2021

4. Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma;Biological and Pharmaceutical Bulletin;2020-10-01

5. Bendamustine;Reactions Weekly;2016-12